News from sorrento therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 05, 2014, 08:45 ET

Sorrento Therapeutics to Present at Two Healthcare Conferences

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...

Aug 26, 2014, 08:45 ET

Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF)

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...

Aug 18, 2014, 07:45 ET

Data Published by Researchers from The Scripps Research Institute Demonstrate Potential for MYC Inhibitor Licensed by Sorrento Therapeutics

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...

Aug 08, 2014, 17:00 ET

Sorrento Therapeutics Appoints Douglas Ebersole to its Board of Directors

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...

Jul 31, 2014, 17:38 ET

Sorrento Announces the Unexpected Death of its Chief Business Officer

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) today announced the death of Mr. Amar Singh, Chief Business Officer and Executive Vice...

Jul 21, 2014, 08:45 ET

Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...

Jul 01, 2014, 08:45 ET

Sorrento Awarded up to $2.6 Million from the National Institutes of Health (NIH) for the Development of New Anti-bacterial Bispecific Antibodies and Antibody Formulated Drug Conjugates

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...

Jun 25, 2014, 08:45 ET

Morphotek and Sorrento Therapeutics Sign an Exclusive Research and Option Agreement to Generate and Develop Morphotek Antibody Drug Conjugates

Concortis Biosystems, Inc. (Concortis), a subsidiary of Sorrento Therapeutics (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company...

Jun 23, 2014, 08:45 ET

Sorrento Therapeutics Announces Confidential Submission of Draft Registration Statement for Initial Public Offering (IPO) of its Wholly-owned Subsidiary Ark Animal Health with the SEC

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...

Jun 20, 2014, 15:15 ET

Sorrento to Present at BIO Business Forum

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"), a late-stage clinical oncology company developing new treatments for cancer and its...

Jun 12, 2014, 20:30 ET

Sorrento Announces Underwriters' Exercise of Over-Allotment Option

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento" or the "Company"), a late-stage clinical oncology company developing new treatments for...

May 30, 2014, 13:49 ET

Sorrento Therapeutics to Present at Jefferies 2014 Global Healthcare Conference

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and...

May 14, 2014, 23:57 ET

Sorrento Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento" or the "Company"), a late-stage clinical oncology company developing new treatments for...

May 14, 2014, 16:40 ET

Sorrento Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Sorrento Therapeutics, Inc. (Nasdaq: SRNE) ("Sorrento" or the "Company"), a late-stage clinical oncology company developing new treatments for...

May 13, 2014, 07:30 ET

Sorrento Announces Transfer of Orphan Drug Designation Sponsorship for Intrathecal Resiniferatoxin from NIH

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and its associated...

Apr 07, 2014, 15:58 ET

Sorrento appoints Ian Walters as Senior Vice President of Translational Medicine and Corporate Development

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and its associated...

Apr 04, 2014, 09:43 ET

Sorrento Therapeutics Announces Key Presentation on Cynviloq at the American Association for Cancer Research Annual Meeting

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...

Apr 04, 2014, 06:00 ET

Sorrento Announces Presentation of Data from Clinical Study of Resiniferatoxin for Intractable Cancer Pain at ASRA Meeting

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new...

Mar 31, 2014, 21:31 ET

Sorrento Announces First Patient Dosed in Registration Trial to Evaluate Bioequivalence Between Cynviloq and Abraxane

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and...

Mar 25, 2014, 07:47 ET

Sorrento Therapeutics Forms Subsidiary Ark Animal Therapeutics to Develop Animal Health Applications

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and...